Pemetrexed News and Research

RSS
Neoadjuvant CPA followed by surgical resection and maintenance atezolizumab meets safety criteria

Neoadjuvant CPA followed by surgical resection and maintenance atezolizumab meets safety criteria

Combination of chemotherapy and immune checkpoint inhibitors shows promise in NSCLC patients with untreated brain metastases

Combination of chemotherapy and immune checkpoint inhibitors shows promise in NSCLC patients with untreated brain metastases

Phase 3 DREAM3R trial opens for malignant pleural mesothelioma

Phase 3 DREAM3R trial opens for malignant pleural mesothelioma

Phase III study of (m)RNA expression did not confer significant advantage for stage II-III lung cancer

Phase III study of (m)RNA expression did not confer significant advantage for stage II-III lung cancer

Nivolumab monotherapy is effective treatment option for relapsed malignant mesothelioma

Nivolumab monotherapy is effective treatment option for relapsed malignant mesothelioma

Novel immunotherapy-plus-chemotherapy combo for pleural mesothelioma shows promise

Novel immunotherapy-plus-chemotherapy combo for pleural mesothelioma shows promise

Durvalumab plus chemotherapy improved overall survival rate for mesothelioma patients

Durvalumab plus chemotherapy improved overall survival rate for mesothelioma patients

NCCN ORP plans to support phase II randomized trial for lung cancer patients

NCCN ORP plans to support phase II randomized trial for lung cancer patients

New combination therapy found to be well tolerated in patients with aggressive brain tumor

New combination therapy found to be well tolerated in patients with aggressive brain tumor

Patients with stage IV disease now living a median 6.8 years after ALK+ NSCLC diagnosis

Patients with stage IV disease now living a median 6.8 years after ALK+ NSCLC diagnosis

Toxic effects of drugs in the lungs 'more widespread than thought'

Toxic effects of drugs in the lungs 'more widespread than thought'

Genentech’s combination therapy improves outcome in patients with non-squamous non-small cell lung cancer

Genentech’s combination therapy improves outcome in patients with non-squamous non-small cell lung cancer

Merck presents MK-1454 Phase 1 data for treatment of advanced solid tumors or lymphomas

Merck presents MK-1454 Phase 1 data for treatment of advanced solid tumors or lymphomas

Merck presents KEYNOTE-057 trial results for patients with high-risk non-muscle invasive bladder cancer

Merck presents KEYNOTE-057 trial results for patients with high-risk non-muscle invasive bladder cancer

CNDA approves KEYTRUDA for treatment of advanced melanoma

CNDA approves KEYTRUDA for treatment of advanced melanoma

Phase 3 study of KEYTRUDA monotherapy meets primary endpoint

Phase 3 study of KEYTRUDA monotherapy meets primary endpoint

Merck announces FDA acceptance of supplemental Biologics License Application for KEYTRUDA

Merck announces FDA acceptance of supplemental Biologics License Application for KEYTRUDA

Neon Therapeutics evaluates safety, efficacy of NEO-PV-01 in combination with KEYTRUDA and chemotherapy

Neon Therapeutics evaluates safety, efficacy of NEO-PV-01 in combination with KEYTRUDA and chemotherapy

Combination immunotherapy as second or third line treatment of mesothelioma shows promising results

Combination immunotherapy as second or third line treatment of mesothelioma shows promising results

FDA approves expanded use of Zykadia for first-line treatment of ALK-positive metastatic NSCLC

FDA approves expanded use of Zykadia for first-line treatment of ALK-positive metastatic NSCLC